Summary
The provided FDA label excerpts only support tolvaptan/JYNARQUE for ADPKD and include a boxed warning for serious liver injury with specific dosing/monitoring requirements. The AI claims mostly concern indications (hyponatremia etiologies), dosing concepts, dosing strength availability, and patient risk factors that are not supported by the supplied label excerpts. The only clearly on-label supported themes from the provided label are serious liver injury and liver monitoring. Because many claims cannot be verified against the provided label text, overall alignment is poor.
Category Scores
Accurate Statements
Tolvaptan requires monitoring during initiation and dose changes.
Supported in BOXED WARNING/Warnings 5.1/Monitoring in 2.2: ALT/AST/bilirubin prior to initiation, at 2 and 4 weeks after initiation, monthly for 18 months, then every 3 months; monitor symptoms indicating liver injury.
Tolvaptan can be associated with a risk of sodium overcorrection.
Not supported by the provided label excerpts (these excerpts focus on serious liver injury in ADPKD). Marked as unsupported below.
Tolvaptan is a vasopressin V2-receptor antagonist.
Not supported by the provided label excerpts.
Tolvaptan targets the vasopressin pathway.
Not supported by the provided label excerpts.
Tolvaptan changes how the body excretes free water.
Not supported by the provided label excerpts.
Unsupported Statements
Tolvaptan is used to treat certain water-balance disorders.
The provided label excerpt (Section 1) indicates JYNARQUE is for slowing kidney function decline in adults at risk of rapidly progressing ADPKD; it does not describe treatment of water-balance disorders.
Tolvaptan is most commonly used to treat hyponatremia (low blood sodium).
Not supported by the provided label excerpt (Section 1).
Tolvaptan can be used for hyponatremia due to heart failure.
Not supported by the provided label excerpt (Section 1); hyponatremia indications are not mentioned.
Tolvaptan can be used for hyponatremia due to cirrhosis.
Not supported by the provided label excerpt (Section 1).
Tolvaptan can be used for hyponatremia due to SIADH.
Not supported by the provided label excerpt (Section 1).
A 15 mg tolvaptan tablet strength exists.
The provided label excerpts do not mention tablet strengths or specific product strengths.
Tolvaptan dosing is indication-specific.
The provided label excerpt describes a specific dosing regimen for ADPKD; it does not address indication-specific dosing generally.
Tolvaptan dosing depends on how low the sodium is.
Not supported; label excerpt is about ADPKD dosing and liver monitoring, not sodium-based adjustment.
Tolvaptan dosing depends on how quickly serum sodium needs to be corrected.
Not supported; not addressed in the provided label excerpts.
Tolvaptan dosing depends on patient risk factors.
The excerpt provides liver injury monitoring and discontinuation rules, but does not describe dosing adjustment based on risk factors.
A 15 mg tablet strength can be used as a starting dose or a titration step under clinician guidance.
The provided label excerpt for dosing (2.1) states initial dosage is 60 mg/day with a specific titration pattern; it does not mention 15 mg as a starting dose for ADPKD.
Tolvaptan is associated with a risk of sodium overcorrection.
Not supported by the provided label excerpts; the provided safety content focuses on serious liver injury.
Sodium overcorrection can be dangerous in severe or high-risk hyponatremia.
Not supported by the provided label excerpts.
In some regions or indications, liver safety monitoring is emphasized for longer-term use of tolvaptan.
Partially similar concept exists (monthly for 18 months and every 3 months thereafter) in provided label, but the statement’s phrasing about “some regions or indications” is not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Tolvaptan is most commonly used to treat hyponatremia (low blood sodium).
Label Reference
Section 1 (Indications and Usage): JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Important Omissions
The provided label excerpts do not support or include the claimed hyponatremia/heart failure/cirrhosis/SIADH indications; the response did not align indications to the label (ADPKD).
Importance:
High
Boxed warning content: the label requires specific ALT/AST/bilirubin timing and strict discontinuation rules; the response did not state these specifics—only general monitoring during initiation and dose changes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes multiple unsupported or label-inconsistent indications (hyponatremia and related etiologies) and sodium correction concepts that are not supported by the provided FDA label excerpts. This could lead to unsafe off-label framing relative to the supplied label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims concern hyponatremia/water-balance disorders and sodium overcorrection, none of which are supported by the provided FDA label excerpts (which instead describe ADPKD and serious liver injury monitoring).
Suggested Improvement
Limit claims to the supplied label: correct indication (ADPKD), describe boxed warning and required liver monitoring schedule and discontinuation guidance, and avoid hyponatremia/sodium-overcorrection/vaptan mechanism claims unless supported by the provided label text.